Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine
Powder-injectors use gas propulsion to deposit lyophilised drug or vaccine particles in the epidermal and sub epidermal layers of the skin. We prepared dry-powder (Tg = 45.2 ± 0.5°C) microparticles (58.1 μm) of a MenY-CRM197 glyconjugate vaccine (0.5% wt.) for intradermal needle-free powder injectio...
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
Public Library of Science
2017
|
| _version_ | 1826281635350315008 |
|---|---|
| author | Weissmueller, N Marsay, L Schiffter, H Carlisle, R Rollier, C Prud'homme, R Pollard, A |
| author_facet | Weissmueller, N Marsay, L Schiffter, H Carlisle, R Rollier, C Prud'homme, R Pollard, A |
| author_sort | Weissmueller, N |
| collection | OXFORD |
| description | Powder-injectors use gas propulsion to deposit lyophilised drug or vaccine particles in the epidermal and sub epidermal layers of the skin. We prepared dry-powder (Tg = 45.2 ± 0.5°C) microparticles (58.1 μm) of a MenY-CRM197 glyconjugate vaccine (0.5% wt.) for intradermal needle-free powder injection (NFPI). SFD used ultrasound atomisation of the liquid vaccine-containing excipient feed, followed by lyophilisation above the glass transition temperature (Tg' = - 29.9 ± 0.3°C). This resulted in robust particles (density~ 0.53 ±0.09 g/cm3) with a narrow volume size distribution (mean diameter 58.1 μm, and span = 1.2), and an impact parameter (ρvr ~ 11.5 kg/m·s) sufficient to breach the Stratum corneum (sc). The trehalose, manitol, dextran (10 kDa), dextran (150 kDa) formulation, or TMDD (3:3:3:1), protected the MenY-CRM197 glyconjugate during SFD with minimal loss, no detectable chemical degradation or physical aggregation. In a capsular group Y Neisseria meningitidis serum bactericidal assay (SBA) with human serum complement, the needle free vaccine, which contained no alum adjuvant, induced functional protective antibody responses in vivo of similar magnitude to the conventional vaccine injected by hypodermic needle and syringe and containing alum adjuvant. These results demonstrate that needle-free vaccination is both technically and immunologically valid, and could be considered for vaccines in development. |
| first_indexed | 2024-03-07T00:31:46Z |
| format | Journal article |
| id | oxford-uuid:800c8186-3dbb-4997-a11e-8faffd607f4a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:31:46Z |
| publishDate | 2017 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:800c8186-3dbb-4997-a11e-8faffd607f4a2022-03-26T21:20:50ZAlternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccineJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:800c8186-3dbb-4997-a11e-8faffd607f4aEnglishSymplectic Elements at OxfordPublic Library of Science2017Weissmueller, NMarsay, LSchiffter, HCarlisle, RRollier, CPrud'homme, RPollard, APowder-injectors use gas propulsion to deposit lyophilised drug or vaccine particles in the epidermal and sub epidermal layers of the skin. We prepared dry-powder (Tg = 45.2 ± 0.5°C) microparticles (58.1 μm) of a MenY-CRM197 glyconjugate vaccine (0.5% wt.) for intradermal needle-free powder injection (NFPI). SFD used ultrasound atomisation of the liquid vaccine-containing excipient feed, followed by lyophilisation above the glass transition temperature (Tg' = - 29.9 ± 0.3°C). This resulted in robust particles (density~ 0.53 ±0.09 g/cm3) with a narrow volume size distribution (mean diameter 58.1 μm, and span = 1.2), and an impact parameter (ρvr ~ 11.5 kg/m·s) sufficient to breach the Stratum corneum (sc). The trehalose, manitol, dextran (10 kDa), dextran (150 kDa) formulation, or TMDD (3:3:3:1), protected the MenY-CRM197 glyconjugate during SFD with minimal loss, no detectable chemical degradation or physical aggregation. In a capsular group Y Neisseria meningitidis serum bactericidal assay (SBA) with human serum complement, the needle free vaccine, which contained no alum adjuvant, induced functional protective antibody responses in vivo of similar magnitude to the conventional vaccine injected by hypodermic needle and syringe and containing alum adjuvant. These results demonstrate that needle-free vaccination is both technically and immunologically valid, and could be considered for vaccines in development. |
| spellingShingle | Weissmueller, N Marsay, L Schiffter, H Carlisle, R Rollier, C Prud'homme, R Pollard, A Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine |
| title | Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine |
| title_full | Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine |
| title_fullStr | Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine |
| title_full_unstemmed | Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine |
| title_short | Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine |
| title_sort | alternative vaccine administration by powder injection needle free dermal delivery of the glycoconjugate meningococcal group y vaccine |
| work_keys_str_mv | AT weissmuellern alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine AT marsayl alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine AT schiffterh alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine AT carlisler alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine AT rollierc alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine AT prudhommer alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine AT pollarda alternativevaccineadministrationbypowderinjectionneedlefreedermaldeliveryoftheglycoconjugatemeningococcalgroupyvaccine |